Accessibility Menu
Jazz Pharmaceuticals Plc logo

Jazz Pharmaceuticals Plc(NASDAQ) JAZZ

Market Cap$16.51BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2007)+1,334%
5 Year+90%
1 Year+111%
1 Month+2%
Premium Feature
Moneyball Superscore
66/100
$254.30
+2.25%
+5.60Today
After hours$254.09-$0.21 (-0.08%)
Jazz Pharmaceuticals Plc last closing stock price
MetricPriceDate
Last closeUSD 254.282026-08-21
Jazz Pharmaceuticals Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+3.8%USD 244.962026-08-14
1 month+1.55%USD 250.412026-07-22
3 month+6.03%USD 239.832026-05-22
Year to date+49.58%USD 170.002025-12-31
1 year+110.97%USD 120.532025-08-21
3 year+81.38%USD 140.192023-08-22
5 year+90.47%USD 133.502021-08-20
Since inception+1,334.18%USD 17.732007-06-01

Jazz Pharmaceuticals Plc Financials at a Glance

Market Cap

$16.51BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$4.60B

Net Income (TTM)

$940.76M

EPS (TTM)

$14.50

P/E Ratio

17.54

Dividend

$0.00

Beta (Volatility)

0.70 (Low)

Price

$254.30

Volume

516,753.587

Open

$248.75

Previous Close

$254.28

Daily Range

$248.55 - $255.85

52-Week Range

$122.50 - $265.05

Estimated Earnings Date

Nov 4, 2026

JAZZ News

A cannabis leaf on top of a $100 bill.

5 Best Cannabis ETFs for 2026 and How to Invest

Keith SpeightsAug 12, 2026
A biotech lab technician using multiple pipettes to load blood samples into test tubes.

5 Best Biotech Stocks for 2026 and How to Invest

Keith SpeightsJul 17, 2026
person holding gummy bear edible an inch from her mouth

4 Best CBD Stocks for 2026 and How to Invest

Keith SpeightsJul 13, 2026
drug development pharmaceutical pharma research researchers doctors

Jazz Pharmaceuticals' Lung Cancer Drug Setback in Late-Stage Trials: Here's Why the Stock Impact May Be More Limited Than It Looks

Jeff SiegelJun 23, 2026
Foolcom-Featured.png

Jazz (JAZZ) Q2 Revenue Rises 2%

Motley Fool Markets TeamAug 6, 2025
Doctor working inside cannabis cultivation facility

Prediction: These Could Be the Best-Performing Cannabis Stocks Through 2030

Prosper Junior BakinyAug 26, 2023
Doctor working inside cannabis cultivation facility

My Top Cannabis Stock to Buy in 2023 and Hold For 10 Years

Prosper Junior BakinyMar 21, 2023
Doctor working inside cannabis cultivation facility

2 Cannabis Stocks That Could Make You Richer

Prosper Junior BakinyFeb 9, 2023
Page 1

JAZZ: Motley Fool Moneyball Superscore

66

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Jazz Pharmaceuticals Plc

Jazz Pharmaceuticals plc makes medicines for rare diseases. These treatments help patients with sleep disorders and cancer. The company focuses on health problems with few options.

Treatments for Rare Conditions

  • Sleep Disorders: Xywav and Xyrem treat narcolepsy and idiopathic hypersomnia, a condition causing extreme daytime sleepiness.
  • Rare Epilepsies: Epidiolex is a plant-based medicine used for seizures in patients with rare syndromes like Lennox-Gastaut.
  • Oncology Medicines: Zepzelca and Ziihera treat advanced lung and biliary tract cancers, which affect the bile ducts.
  • Hematology Treatments: Rylaze and Enrylaze are chemotherapy components for patients with specific blood cancers.

Strategic Deals and Growth

  • Acquired Chimerix in April 2025 to add a treatment for a rare and aggressive form of brain tumor.
  • Launched Ziihera in Dec. 2024 for patients with advanced biliary tract cancer following a licensing agreement.
  • Partnered with AbCellera in June 2026 to discover new antibody therapies for solid tumors.
  • Purchased all remaining rights to a conditionally activated molecule from Werewolf Therapeutics in May 2026.

Science-Driven Global Operations

The company maintains its own manufacturing facilities in Ireland, Italy, and the United Kingdom. Its research efforts prioritize highly differentiated treatments for small groups of patients with high medical needs.

By the Numbers

  • Total revenues reached $1.2 billion in the three-month period ended June 30, 2026, up 16% year over year.
  • Net product sales for Epidiolex were $292.1 million in the second quarter of 2026, a 16% increase year over year.
  • Cash and investments totaled $2.2 billion as of June 30, 2026.
  • Operating cash flow reached $823.9 million for the six-month period ended June 30, 2026.
  • The company recognized a $122.8 million gain from the sale of a priority review voucher in Jan. 2026.

The Big Picture

Jazz has transformed from a sleep-focused firm into a diversified player in neuroscience and oncology. This evolution relies on a balance of internal innovation and targeted business acquisitions.

AI Generated • Aug 4, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

2,890

CEO

Renée D. Galá, MBA

Website

www.jazzpharma.com

Headquarters

Dublin, DU D04 E5W7, IE

JAZZ Financials

Key Financial Metrics (TTM)

Gross Margin

84.67%

Operating Margin

31.05%

Net Income Margin

20.45%

Return on Equity

21.37%

Return on Capital

2.30%

Return on Assets

8.49%

Earnings Yield

5.70%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$16.51BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

64.91M

Volume

516.75K

Avg. Volume

821.49K

Financials (TTM)

Gross Profit

$3.90B

Operating Income

$1.43B

EBITDA

$1.48B

Operating Cash Flow

$1.66B

Capital Expenditure

-$118.70M

Free Cash Flow

$1.54B

Cash & ST Invst.

$2.20B

Total Debt

$4.41B

Jazz Pharmaceuticals Plc Performance Analysis

Jazz Pharmaceuticals Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 3,659,374,00018.3%
20232023-12-31USD 3,834,204,0004.8%
20242024-12-31USD 4,068,950,0006.1%
20252025-12-31USD 4,267,586,0004.9%
Jazz Pharmaceuticals Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-307.7%
Q42025-12-316.4%
Q12026-03-31-10.8%
Q22026-06-3013.0%
Jazz Pharmaceuticals Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -3.58-35.1%
20232023-12-31USD 6.10N/A
20242024-12-31USD 8.6541.7%
20252025-12-31USD -5.84N/A
Jazz Pharmaceuticals Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30134.8%
Q42025-12-31-18.1%
Q12026-03-3132.6%
Q22026-06-30-37.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$1.21B

+15.5%

Gross Profit

$1.09B

+17.5%

Gross Margin

90.37%

N/A

Market Cap

$16.51BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$5.71M

N/A

Employees

2,890

N/A

Net Income

$192.80M

+126.8%

EBITDA

$418.10M

+181.3%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$2.20B

+31.7%

Total Debt

$4.41B

-18.8%

Accounts Receivable

$880.90M

+23.4%

Inventory

$443.00M

-12.3%

Long Term Debt

$3.38B

-23.1%

Short Term Debt

$1.03B

-1.1%

Return on Assets

8.49%

N/A

Return on Invested Capital

16.14%

N/A

Free Cash Flow

$397.60M

+294.1%

Operating Cash Flow

$415.70M

+367.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
HALOHalozyme Therapeutics, Inc.
$108.17+1.93%
MDGLMadrigal Pharmaceuticals, Inc.
$516.74-0.45%
AXSMAxsome Therapeutics, Inc.
$207.77-0.12%
CYTKCytokinetics, Incorporated
$76.84-0.44%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.77+0.10%
IBITiShares Bitcoin Trust
$43.68+0.06%
BITOProShares Trust - ProShares Bitcoin ETF
$10.41+0.06%
MARAMara Holdings
$11.26+0.01%

Questions About JAZZ

What is the current price of Jazz Pharmaceuticals Plc?

Jazz Pharmaceuticals Plc is trading at $254.28 per share.

What is the 52-week range for Jazz Pharmaceuticals Plc?

Over the past 52 weeks, Jazz Pharmaceuticals Plc has traded between $122.50 and $265.05.

How much debt does Jazz Pharmaceuticals Plc have?

As of the most recent reporting period, Jazz Pharmaceuticals Plc reported total debt of $4.41B.

How much cash does Jazz Pharmaceuticals Plc have on hand?

Jazz Pharmaceuticals Plc reported $1.62B in cash and cash equivalents in its most recent financial results.

What is Jazz Pharmaceuticals Plc’s dividend yield?

Jazz Pharmaceuticals Plc does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services